Published in Nat Immunol on July 29, 2012
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J Immunol (2014) 1.96
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis (2013) 1.25
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ (2013) 1.25
Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol (2013) 1.22
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med (2013) 1.17
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity (2016) 1.06
Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol (2013) 1.05
Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol (2012) 1.04
Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol (2014) 1.03
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. Front Immunol (2015) 1.01
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ (2016) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol (2013) 0.94
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant (2013) 0.92
The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol (2013) 0.91
Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology (2013) 0.89
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2016) 0.89
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Mol Med (2015) 0.89
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review. Int J Mol Sci (2015) 0.88
Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol (2015) 0.87
MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha. Cell Mol Immunol (2012) 0.87
Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol (2014) 0.86
Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology (2014) 0.86
Innate immune signaling and regulation in cancer immunotherapy. Cell Res (2016) 0.86
The impact of the TIM gene family on tumor immunity and immunosuppression. Cell Mol Immunol (2013) 0.85
Regulation of T cell responses by the receptor molecule Tim-3. Immunol Res (2014) 0.84
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. Clin Cancer Res (2016) 0.83
Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets. Front Immunol (2015) 0.83
Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol (2013) 0.83
The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. Adv Cancer Res (2015) 0.83
The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia. Nat Commun (2015) 0.82
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? J Immunol Res (2016) 0.81
TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS One (2015) 0.81
Parapharyngeal liposarcoma: a case report. Diagn Pathol (2013) 0.81
Interferon response factor 3 is crucial to poly-I:C induced NK cell activity and control of B16 melanoma growth. Cancer Lett (2013) 0.81
Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models. Oncoimmunology (2012) 0.80
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation. J Exp Med (2015) 0.80
DAMPs, MAMPs, and NAMPs in plant innate immunity. BMC Plant Biol (2016) 0.80
Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80
Tim-3 protects decidual stromal cells from toll-like receptor-mediated apoptosis and inflammatory reactions and promotes Th2 bias at the maternal-fetal interface. Sci Rep (2015) 0.79
Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol (2014) 0.79
Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus. Immunology (2015) 0.79
Increased plasma cell-free DNA level during HTNV infection: correlation with disease severity and virus load. Viruses (2014) 0.79
Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Front Immunol (2015) 0.79
Role of dendritic cells in the regulation of antitumor immunity. Oncoimmunology (2013) 0.79
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene (2016) 0.79
T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78
MicroRNA-223 Promotes Type I Interferon Production in Antiviral Innate Immunity by Targeting Forkhead Box Protein O3 (FOXO3). J Biol Chem (2016) 0.78
PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Res (2015) 0.78
High-mobility group box 1 (HMGB1) in childhood: from bench to bedside. Eur J Pediatr (2014) 0.78
Dynamic localization and the associated translocation mechanism of HMGBs in response to GCRV challenge in CIK cells. Cell Mol Immunol (2014) 0.78
Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma. J Mol Histol (2012) 0.78
T Cell Immunoglobulin Mucin Domain (TIM)-3 Promoter Activity in a Human Mast Cell Line. Immune Netw (2012) 0.78
Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev (2017) 0.78
Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol (2016) 0.78
Tim-3 and Tim-4 as the potential targets for antitumor therapy. Hum Vaccin Immunother (2015) 0.77
Up-regulation of Tim-3 on T cells during acute simian immunodeficiency virus infection and on antigen specific responders. AIDS (2015) 0.77
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev (2017) 0.77
Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases. Front Immunol (2016) 0.77
Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction. Lab Invest (2014) 0.77
Blockage of Galectin-receptor Interactions by α-lactose Exacerbates Plasmodium berghei-induced Pulmonary Immunopathology. Sci Rep (2016) 0.77
RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression. Stem Cells Transl Med (2014) 0.76
Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. Oncoimmunology (2016) 0.76
TIM-3 Regulates Distinct Functions in Macrophages. Front Immunol (2016) 0.76
Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget (2016) 0.76
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology (2015) 0.76
Toll-like receptor 4 signaling: A common pathway for interactions between prooxidants and extracellular disulfide high mobility group box 1 (HMGB1) protein-coupled activation. Biochem Pharmacol (2015) 0.76
Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response. MAbs (2014) 0.76
Quantitative assessment of TIM-3 polymorphisms and cancer risk in Chinese Han population. Oncotarget (2016) 0.76
The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: a meta-analysis and literature review. Onco Targets Ther (2016) 0.76
Regulatory mechanisms of nucleic acid-mediated innate immune responses in the tumor microenvironment. Oncoimmunology (2012) 0.76
Plasma levels of Galectin-9 reflect disease severity in malaria infection. Malar J (2016) 0.76
T cell immunoglobulin and mucin domain-containing molecule 3 on CD14(+) monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes mellitus. J Diabetes Investig (2016) 0.75
TIM-3, a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections. Austin Virol Retro Virol (2014) 0.75
Immunology: TIM3 suppresses antitumour DCs. Nat Rev Cancer (2012) 0.75
The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy. Cancer Cell Int (2014) 0.75
Stimulation through CD40 and TLR-4 Is an Effective Host Directed Therapy against Mycobacterium tuberculosis. Front Immunol (2016) 0.75
Tumour immunology: TIM3 suppresses antitumour DCs. Nat Rev Immunol (2012) 0.75
Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). Iran J Basic Med Sci (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Immunity, inflammation, and cancer. Cell (2010) 28.27
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Taking dendritic cells into medicine. Nature (2007) 11.82
Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell (2008) 9.59
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07
Intracellular toll-like receptors. Immunity (2010) 4.66
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity (2012) 2.54
Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med (2007) 2.48
Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity (2007) 2.29
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 2.27
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity (2007) 1.92
T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol (2010) 1.79
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A (2011) 1.71
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
New roles for TIM family members in immune regulation. Nat Rev Immunol (2008) 1.68
Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol (2010) 1.66
Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol (2008) 1.66
Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med (2010) 1.66
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 1.66
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell (2010) 1.64
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses. PLoS One (2011) 1.05
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest (2011) 1.01
Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol (2008) 1.01
High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding. J Biol Chem (2005) 0.97
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Induction of colonic regulatory T cells by indigenous Clostridium species. Science (2010) 16.71
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 13.23
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature (2005) 6.14
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature (2005) 5.37
Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity (2006) 5.36
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Activation of rac and cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes in the membrane of living cells. Mol Cell Biol (2002) 4.50
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity (2007) 4.49
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA (2002) 4.32
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Activity of Rho-family GTPases during cell division as visualized with FRET-based probes. J Cell Biol (2003) 3.85
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res (2010) 3.40
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta (2002) 3.35
Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A (2003) 3.29
Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A (2008) 3.27
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol (2005) 3.23
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer (2006) 3.19
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J (2003) 2.97
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res (2005) 2.97
Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci U S A (2004) 2.89
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol (2002) 2.85
A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82
Regulation of the type I IFN induction: a current view. Int Immunol (2005) 2.82
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem (2005) 2.71
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res (2005) 2.53
Integral role of Noxa in p53-mediated apoptotic response. Genes Dev (2003) 2.50
Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol (2008) 2.48
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest (2011) 2.40
Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A (2005) 2.39
Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock. Biochem Biophys Res Commun (2003) 2.37
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 2.27
OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med (2003) 2.26
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 2.21
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology (2004) 2.18
Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol (2003) 2.16
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood (2008) 2.12
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension (2004) 2.10
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys (2003) 2.00
Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J Immunol (2014) 1.96
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci (2009) 1.95
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med (2007) 1.93
Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity (2004) 1.93
Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun (2003) 1.91
Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol (2010) 1.91
Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun (2009) 1.89
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med (2003) 1.85
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer (2007) 1.85